Michael Ehlers, Ascidian Therapeutics CEO (Photo: Kevin Trimmer)
June 18, 2024 07:00 AM EDT
Startups
Deals

Roche strikes neu­ro-fo­cused part­ner­ship with RNA ex­on edit­ing start­up, worth as much as $1.8B

Ryan Cross

Senior Science Correspondent

Roche has tapped a small Boston start­up for ac­cess to a sweep­ing form of RNA edit­ing that re­places large swathes of er­rant ge­net­ic code. Broad­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times